Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

15.30USD
21 Sep 2018
Change (% chg)

$0.41 (+2.75%)
Prev Close
$14.89
Open
$14.82
Day's High
$15.31
Day's Low
$14.71
Volume
2,398,394
Avg. Vol
657,688
52-wk High
$20.20
52-wk Low
$10.03

Latest Key Developments (Source: Significant Developments)

U.S. FDA Approves Array Biopharma's NDA For Mektovi
Wednesday, 27 Jun 2018 01:07pm EDT 

June 27 (Reuters) - U.S. Food and Drug Administration::U.S. FDA APPROVES ARRAY BIOPHARMA'S NDA FOR MEKTOVI.U.S. FDA SAYS RECOMMENDED DOSE FOR ARRAY'S MEKTOVI IS 45 MG ORALLY TWICE DAILY IN COMBINATION WITH ENCORAFENIB.U.S. FDA SAYS MEKTOVI IS INDICATED, IN COMBINATION WITH ENCORAFENIB, FOR TREATING PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF MUTATION.  Full Article

Array Biopharma Announces Additional Median Overall Survival Results Of Encorafenib And Binimetinib
Monday, 4 Jun 2018 08:00am EDT 

June 4 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA ANNOUNCES ADDITIONAL MEDIAN OVERALL SURVIVAL RESULTS OF ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF-MUTANT ADVANCED MELANOMA.ARRAY BIOPHARMA INC - COMBINATION OF ENCORAFENIB AND BINIMETINIB ACHIEVED 33.6 MONTH MEDIAN OVERALL SURVIVAL.  Full Article

Array Biopharma Says Entered Into Controlled Equity Offerings Sales Agreement With Cantor Fitzgerald
Wednesday, 9 May 2018 08:37am EDT 

May 9 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA INC SAYS ENTERED INTO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT WITH CANTOR FITZGERALD & CO - SEC FILING.ARRAY BIOPHARMA INC SAYS MAY OFFER AND SELL UP TO $125.0 MILLION OF COMMON STOCK OF THROUGH CANTOR FITZGERALD & CO.  Full Article

Array Biopharma Q2 Loss Per Share $0.17
Tuesday, 6 Feb 2018 08:05am EST 

Feb 6 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2018.Q2 LOSS PER SHARE $0.17.Q2 REVENUE $42.2 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.23, REVENUE VIEW $26.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Array Biopharma Contributes Rights And Assets Related To Arry-797 Drug Program To Yarra Therapeutics
Friday, 22 Dec 2017 06:12am EST 

Dec 22 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA SAYS ON DEC 21, CO CONTRIBUTED CERTAIN RIGHTS AND ASSETS RELATED TO ARRY-797 DRUG PROGRAM TO YARRA THERAPEUTICS - SEC FILING.ARRAY BIOPHARMA SAYS FORMED YARRA TO FURTHER DEVELOP, COMMERCIALIZE THERAPEUTICS TARGETED TOWARDS RARE DISEASES, INCLUDING ARRY-797 DRUG PROGRAM.ARRAY BIOPHARMA - YARRA WILL BE LED BY BRYAN STUART, WHO WILL SERVE AS YARRA'S PRESIDENT AND CHIEF EXECUTIVE OFFICER.  Full Article

Array BioPharma Announces Strategic Collaboration With Pfizer
Tuesday, 19 Dec 2017 08:00am EST 

Dec 19 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA ANNOUNCES STRATEGIC COLLABORATION WITH PFIZER.ARRAY BIOPHARMA SAYS UNDER COLLABORATION AGREEMENT, TRIAL WILL BE SPONSORED AND FUNDED BY PFIZER, WITH ARRAY PROVIDING BINIMETINIB SUPPLY.ARRAY BIOPHARMA - PHASE 1B CLINICAL STUDY IS EXPECTED TO BEGIN BY Q3 2018.ARRAY BIOPHARMA - ENTERED INTO CLINICAL TRIAL AGREEMENT WITH PFIZER TO INVESTIGATE SAFETY, EFFICACY OF SEVERAL NOVEL ANTI-CANCER COMBINATIONS.  Full Article

Array - In Exchange For $126.06 Million 3.00% Convertible Senior Notes Co Issued 2024 $126.06 Million Notes
Monday, 4 Dec 2017 04:42pm EST 

Dec 4 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA - ‍ON DEC 1, IN EXCHANGE FOR $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020 CO ISSUED 2024 NOTES OF $126.06 MILLION.ARRAY BIOPHARMA SAYS ‍2024 NOTES WILL MATURE ON DEC 1, 2024​ - SEC FILING.ARRAY - ALSO ISSUED AGGREGATE OF ABOUT 7.96 MILLION SHARES OF CO'S COMMON STOCK IN EXCHANGE OF $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020​.ARRAY BIOPHARMA - ‍2024 NOTES TO BEAR INTEREST AT 2.625% PAYABLE SEMIANNUALLY IN ARREARS ON JUNE 1 & DEC 1 OF EACH YEAR, BEGINNING JUNE 1, 2018​.  Full Article

Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting
Monday, 13 Nov 2017 08:00am EST 

Nov 13 (Reuters) - Array Biopharma Inc :Array biopharma reports initial results from novel immunotherapy combination at the Society For Immunotherapy Of Cancer (SITC) 32nd annual meeting.Array Biopharma Inc - ‍plans to expand ongoing phase 2 CSF1R + PD1 combination study into other tumor types including pancreatic cancer​.  Full Article

ARRAY BIOPHARMA REPORTS Q1 LOSS PER SHARE $0.22
Tuesday, 31 Oct 2017 08:00am EDT 

Oct 31 (Reuters) - Array Biopharma Inc :ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2018.Q1 LOSS PER SHARE $0.22.Q1 REVENUE $29.7 MILLION VERSUS I/B/E/S VIEW $33.3 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.‍INCREASE IN QTRLY NET LOSS WAS PRIMARILY DUE TO A DECREASE IN REIMBURSEMENT REVENUE FROM NOVARTIS​.‍INCREASE IN QTRLY NET LOSS WAS ALSO PRIMARILY DUE TO A DECREASE IN NON-RECURRING COSTS FOR COMMERCIAL DRUG SUPPLY FROM NOVARTIS​.  Full Article

Array Biopharma announces proposed public offering of common stock
Wednesday, 13 Sep 2017 04:02pm EDT 

Sept 14 (Reuters) - Array Biopharma Inc :Array Biopharma announces proposed public offering of common stock.Array Biopharma Inc - ‍commenced an underwritten public offering of $175 million of shares of its common stock.​.  Full Article

Photo

Array BioPharma gets FDA nod for melanoma combo treatment

The U.S. Food and Drug Administration said on Wednesday it approved Array BioPharma Inc's oral combination treatment for use in patients with the deadliest form of skin cancer.